University Hospitals Cleveland Medical Center

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on: 
Friday, November 3, 2023
CR, Neoplasm, Survival, WT1, MTD, DOI, H. Lee Moffitt Cancer Center & Research Institute, OH, Stomach, PDT, Ovarian cancer, EDT, Pembrolizumab, Nucleic acid thermodynamics, Infrared spectroscopy correlation table, DCR, MOS, HPV, Docetaxel, Chair, HNSCC, CPS, Phase, SITC, Cetuximab, Immunotherapy, SD, Clinical trial, Immune system, University Hospitals Cleveland Medical Center, Cancer, ORR, Blood, Methotrexate, EW, Society for Immunotherapy of Cancer, DSD, Safety, Society, Checkmate, Patient, DNA, UPR, Pharmaceutical industry, Vaccine, Communications satellite, Head, Lancet

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points: 
  • New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
  • I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
  • Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Tuesday, October 31, 2023
University Hospitals Coventry and Warwickshire NHS Trust, Cartilage, NHS trust, Research, Trust, Surgeon, University Hospitals Cleveland Medical Center, Chondrocyte, Knee, Patient

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day with very little postoperative discomfort," said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFT

Retrieved on: 
Tuesday, October 31, 2023
University Hospitals Coventry and Warwickshire NHS Trust, Cartilage, NHS trust, Research, Trust, Surgeon, University Hospitals Cleveland Medical Center, Chondrocyte, Knee, Patient, Medical device

CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.

Key Points: 
  • CENTENNIAL, Colo., Oct. 31, 2023 /PRNewswire/ -- AlloSource® , one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent evaluation.
  • The procedure was conducted by Dr. Nick Smith, D.O., a knee specialist orthopedic surgeon with University Hospitals Coventry and Warwickshire, NHS Trust.
  • "The operation went very well and the patient was discharged the same day..." said Dr. Nick Smith.
  • The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group.

CPL Acquires Ohio-Based Firm to Expand Services into the Midwest

Retrieved on: 
Monday, October 30, 2023
Education, Cuyahoga Community College, MPA, Oberlin College, Acquisition, Creativity, AIA, CPL, City, Culture, Public sector, Cleveland, Kent State University, NCARB, Semen Makovich, University Hospitals Cleveland Medical Center, MetroHealth, Cleveland Clinic, Management

The move combines MPA's portfolio and knowledge base in healthcare, higher education, and the public sector with CPL's innovative design approach and client-service expertise.

Key Points: 
  • The move combines MPA's portfolio and knowledge base in healthcare, higher education, and the public sector with CPL's innovative design approach and client-service expertise.
  • "Culture is key and MPA brings the same energy and values to their business and clients as CPL.
  • "When seeking a partner, our goal was to find a firm that shares a common set of core principles and mission-driven values," said Don Rerko, AIA, NCARB, president, MPA.
  • "The opportunity to join the CPL team will allow us to broaden our scope and scale our services more quickly to meet the growing needs of clients."

University Hospitals partners with Luna to expand access to in-home, in-person, outpatient physical therapy services

Retrieved on: 
Tuesday, October 24, 2023
Patient, MOT, Home, MBA, Entrepreneurship, Geography, Partnership, Therapy, University Hospitals Cleveland Medical Center, UH, Hospital, Nursing, Pharmaceutical industry, Q4

NASHVILLE, Tenn. and CLEVELAND, Oct. 24, 2023 /PRNewswire/ -- University Hospitals (UH), one of the nation's leading healthcare systems based in Cleveland, Ohio, has joined forces with Luna , the leading provider of in-home, in-person outpatient physical therapy, to expand access to services.

Key Points: 
  • NASHVILLE, Tenn. and CLEVELAND, Oct. 24, 2023 /PRNewswire/ -- University Hospitals (UH), one of the nation's leading healthcare systems based in Cleveland, Ohio, has joined forces with Luna , the leading provider of in-home, in-person outpatient physical therapy, to expand access to services.
  • The new collaboration, known as University Hospitals Physical Therapy At Home, will start taking appointments in Q4, 2023.
  • The University Hospitals Physical Therapy At Home service will be covered by most major insurances with the same co-pay cost as facility-based care.
  • "Health systems are turning to Luna to expand access to physical therapy beyond the geographic limits of their facilities," said Palak Shah, Co-Founder and Head of Clinical Operations at Luna.

GE HealthCare and University Hospitals Enter 10-Year Strategic Collaboration to Contemporize Its Imaging Fleet and Implement Enterprise Digital Solutions to Help Improve Patient Care and Optimize Processes

Retrieved on: 
Thursday, October 5, 2023
Managed Care, Other Health, Radiology, Pharmaceutical, Data Management, Technology, University, Artificial Intelligence, Health Technology, Education, Cardiology, Other Technology, Health, Multimedia, MBA, Physician, Student, Machine learning, University Hospitals Cleveland Medical Center, AI, MD, Nuclear medicine, Command center, Workflow, CT, UH, GE HealthCare, GE, Software, Overalls, Patient, Fluoroscopy, Medical imaging, Nursing, Medical device

A focus of the collaboration is to implement enterprise-wide technology to optimize workflows and help improve clinical decision-making.

Key Points: 
  • A focus of the collaboration is to implement enterprise-wide technology to optimize workflows and help improve clinical decision-making.
  • These issues underscore the need for more efficient workflows and a real-time decision-making solution to optimize hospital operations and patient care.
  • Standardization and automated protocols across CT devices to help improve workflow, increase utilization and reduce the downtime associated with managing the fleet.
  • A digital Command Center solution that leverages technology and insights at the enterprise-level through a cloud-based digital hub for UH’s radiology department.

Sherwin-Williams Board of Directors Elects Heidi Petz CEO Effective January 1, 2024

Retrieved on: 
Wednesday, October 11, 2023
SHW, MBA, NYSE, Acquisition, Loyola University Maryland, PwC, Sherwin-Williams, University of Richmond, HBO Latin America Group, University, Ulta Beauty, Target Corporation, University Hospitals Cleveland Medical Center, Webcast, Growth, Policy, Valspar, EDT, Loyola University, Newell Brands, Management

CLEVELAND, Oct. 11, 2023 /PRNewswire/ -- The Sherwin-Williams Company (NYSE: SHW) announced today that its Board of Directors has elected Heidi G. Petz to serve as the Company's next Chief Executive Officer (CEO), effective January 1, 2024. Ms. Petz, 48, who has served as President and Chief Operating Officer of Sherwin-Williams for the last two years, will assume the CEO duties currently held by Chairman and CEO John G. Morikis. Ms. Petz will continue to serve as President. After serving as CEO since 2016, Mr. Morikis will continue to serve as Executive Chairman. In addition, the Board increased its size from 10 to 11 members and elected Ms. Petz to fill the resulting vacancy, effective October 10, 2023.

Key Points: 
  • CLEVELAND, Oct. 11, 2023 /PRNewswire/ -- The Sherwin-Williams Company (NYSE: SHW) announced today that its Board of Directors has elected Heidi G. Petz to serve as the Company's next Chief Executive Officer (CEO), effective January 1, 2024.
  • After serving as CEO since 2016, Mr. Morikis will continue to serve as Executive Chairman.
  • In addition, the Board increased its size from 10 to 11 members and elected Ms. Petz to fill the resulting vacancy, effective October 10, 2023.
  • With this transition, Heidi becomes only the tenth CEO in the 157-year history of the Company.

Cleveland Browns Tight End David Njoku Supports the American Burn Association By Launching Exclusive "WITHSTAND" Merchandise Line on MILLIONS

Retrieved on: 
Tuesday, October 10, 2023
MBA, Cut, Burn, NFL, University Hospitals Cleveland Medical Center, MD, Cutting off one's nose to spite one's face, CAE, ABA, Arm, Patient, Collection, Education, American Burn Association, Survivor, MAWI, Face, Life, Research, Sale, Nursing, Department store, Njoku, Cleveland Browns

CLEVELAND, Oct. 10, 2023 /PRNewswire/ - Cleveland Browns tight end, David Njoku, is proud to announce the launch of an exclusive merchandise line to raise awareness, resources, and support for burn-related care, prevention, education, and research.

Key Points: 
  • CLEVELAND, Oct. 10, 2023 /PRNewswire/ - Cleveland Browns tight end, David Njoku, is proud to announce the launch of an exclusive merchandise line to raise awareness, resources, and support for burn-related care, prevention, education, and research.
  • The merchandise line will be available on David Njoku's MILLIONS.co profile, and a portion of the proceeds from each sale will be donated to the American Burn Association (ABA).
  • The American Burn Association, represented by Chief Executive, Kimberly Hoarle, MBA, CAE, is thankful to David Njoku for undertaking this meaningful endeavor.
  • For more information about David Njoku's merchandise line and to make a difference in the lives of burn survivors, please visit https://millions.co/david-njoku .

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

Retrieved on: 
Wednesday, October 4, 2023
Health, Genetics, Radiology, Clinical Trials, Oncology, Docetaxel, NRG, Prostate-specific antigen, Radiation, University, DM, ASTRO, MFS, Clinical trial, University Hospitals Cleveland Medical Center, ADT, Research, Risk, Prostate, Gene expression, Radiation therapy, Maryland School, University of Maryland School of Medicine, Patient, Physician, Annual general meeting, Case Western Reserve University School of Medicine, Urology, Society, PSA, American Society for Radiation Oncology, Biopsy, Prostate cancer, Medical imaging

(Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.
  • Data from a second study presented at ASTRO 2023 reveal there is minimal to moderate risk-score correlation between the gene expression signatures of three commercially available genomic classifiers, including the Decipher Prostate test.
  • Researchers generated Decipher Prostate test scores using biopsy samples from 183 patients, who were followed for a median of 9.9 years.
  • Additionally, patients with higher-risk Decipher Prostate genomic scores had worse DM (sHR 2.82, 95% CI) compared to those with lower-risk scores.

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Disease, Drug development, University, Therapy, 100,000 Genomes Project, Rare disease, University Hospitals Cleveland Medical Center, Hope, University of Oxford, Research, Genomics, OHC, OXFORD, DSM-IV codes, Translation, Oxford Sciences Enterprises, MD, Patient, Investment, Cancer, Genomics England, Department of Biology, University of Oxford, Motivation, Accelerator, Foreign policy, Rare, Courage, Family, Harrington, Pharmaceutical industry, Hospital, Nursing, Vaccine, Management, Neuroscience, Medicine, Pediatrics

Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.

Key Points: 
  • Former U.K. Prime Minister David Cameron to lead the international efforts of the Accelerator as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.
  • The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
  • The partners are also collaborating to create a dedicated Rare Disease Impact Fund to enable investments in mission-aligned projects and accelerate the development of rare disease therapeutics.
  • For academics and researchers to find out more about the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre and how to apply, please go to OxfordHarrington.org .